Compare Abbott India with STRIDES PHARMA SCIENCE - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ABBOTT INDIA vs STRIDES PHARMA SCIENCE - Comparison Results

ABBOTT INDIA     Change

Formerly known as Knoll Pharmaceuticals Limited, Abbott India Limited (AIL) is a subsidiary of Abbott Capital India Limited in which the latter holds about 69% stake. It is involved in the discovery, development, manufacture and marketing of pharmace... More

STRIDES PHARMA SCIENCE 
   Change

Strides Arcolab is an Indian pharmaceutical company headquartered at Bangalore. The company is primarily involved in two businesses notably the pharma business and the specialized sterile products business branded as Agila. This segment focuses large... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ABBOTT INDIA STRIDES PHARMA SCIENCE ABBOTT INDIA/
STRIDES PHARMA SCIENCE
 
P/E (TTM) x 43.6 15.1 289.0% View Chart
P/BV x 12.5 0.9 1,400.6% View Chart
Dividend Yield % 0.6 0.5 101.4%  

Financials

 ABBOTT INDIA   STRIDES PHARMA SCIENCE
EQUITY SHARE DATA
    ABBOTT INDIA
Mar-18
STRIDES PHARMA SCIENCE
Mar-18
ABBOTT INDIA/
STRIDES PHARMA SCIENCE
5-Yr Chart
Click to enlarge
High Rs6,1101,147 532.7%   
Low Rs3,996642 622.4%   
Sales per share (Unadj.) Rs1,552.2317.2 489.3%  
Earnings per share (Unadj.) Rs188.87.8 2,406.8%  
Cash flow per share (Unadj.) Rs196.425.1 783.9%  
Dividends per share (Unadj.) Rs55.002.00 2,750.0%  
Dividend yield (eoy) %1.10.2 486.8%  
Book value per share (Unadj.) Rs796.6274.3 290.5%  
Shares outstanding (eoy) m21.2589.50 23.7%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x3.32.8 115.5%   
Avg P/E ratio x26.8114.0 23.5%  
P/CF ratio (eoy) x25.735.7 72.1%  
Price / Book Value ratio x6.33.3 194.5%  
Dividend payout %29.125.5 114.3%   
Avg Mkt Cap Rs m107,37680,058 134.1%   
No. of employees `0003.32.5 132.5%   
Total wages/salary Rs m3,9374,341 90.7%   
Avg. sales/employee Rs Th9,929.311,325.8 87.7%   
Avg. wages/employee Rs Th1,185.11,731.4 68.4%   
Avg. net profit/employee Rs Th1,207.7280.1 431.2%   
INCOME DATA
Net Sales Rs m32,98528,394 116.2%  
Other income Rs m1,170941 124.4%   
Total revenues Rs m34,15529,334 116.4%   
Gross profit Rs m5,2453,965 132.3%  
Depreciation Rs m1621,540 10.5%   
Interest Rs m381,962 1.9%   
Profit before tax Rs m6,2151,403 442.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m0-168 0.0%   
Extraordinary Inc (Exp) Rs m0-436 0.0%   
Tax Rs m2,20397 2,263.8%   
Profit after tax Rs m4,012702 571.4%  
Gross profit margin %15.914.0 113.9%  
Effective tax rate %35.46.9 511.1%   
Net profit margin %12.22.5 491.9%  
BALANCE SHEET DATA
Current assets Rs m22,65524,836 91.2%   
Current liabilities Rs m6,68118,993 35.2%   
Net working cap to sales %48.420.6 235.3%  
Current ratio x3.41.3 259.3%  
Inventory Days Days6571 91.3%  
Debtors Days Days29113 25.7%  
Net fixed assets Rs m83534,289 2.4%   
Share capital Rs m213895 23.7%   
"Free" reserves Rs m16,71523,651 70.7%   
Net worth Rs m16,92824,546 69.0%   
Long term debt Rs m015,513 0.0%   
Total assets Rs m24,16265,437 36.9%  
Interest coverage x163.71.7 9,544.4%   
Debt to equity ratio x00.6 0.0%  
Sales to assets ratio x1.40.4 314.6%   
Return on assets %16.84.1 411.7%  
Return on equity %23.72.9 828.6%  
Return on capital %36.96.9 535.8%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m36915,697 2.3%   
Fx outflow Rs m3,807735 517.6%   
Net fx Rs m-3,43814,962 -23.0%   
CASH FLOW
From Operations Rs m1,5271,871 81.6%  
From Investments Rs m-2,1485,826 -36.9%  
From Financial Activity Rs m-1,024-10,157 10.1%  
Net Cashflow Rs m-1,646-2,615 62.9%  

Share Holding

Indian Promoters % 0.0 27.7 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 7.9 37.8 20.9%  
FIIs % 0.1 8.6 1.2%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.1 25.9 66.0%  
Shareholders   18,270 56,241 32.5%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ABBOTT INDIA With:   DR. DATSONS LABS  DISHMAN PHARMA  J.B.CHEMICALS  JUBILANT LIFE SCIENCES  DIVIS LABORATORIES  

Compare ABBOTT INDIA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 82 Points Higher; Metal and Realty Stocks Witness Buying(Closing)

Indian share markets ended their trading session marginally higher. On the sectoral front, gains were seen in the metal sector and realty sector.

Related Views on News

ABBOTT INDIA Announces Quarterly Results (1QFY20); Net Profit Up 41.9% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, ABBOTT INDIA has posted a net profit of Rs 1 bn (up 41.9% YoY). Sales on the other hand came in at Rs 10 bn (up 18.2% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

STRIDES PHARMA SCIENCE Announces Quarterly Results (1QFY20); Net Profit Up 1048.1% (Quarterly Result Update)

Jul 31, 2019 | Updated on Jul 31, 2019

For the quarter ended June 2019, STRIDES PHARMA SCIENCE has posted a net profit of Rs 432 m (up 1048.1% YoY). Sales on the other hand came in at Rs 7 bn (up 3.4% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

ABBOTT INDIA Announces Quarterly Results (4QFY19); Net Profit Up 13.1% (Quarterly Result Update)

May 28, 2019 | Updated on May 28, 2019

For the quarter ended March 2019, ABBOTT INDIA has posted a net profit of Rs 1 bn (up 13.1% YoY). Sales on the other hand came in at Rs 9 bn (up 15.0% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

STRIDES PHARMA SCIENCE Announces Quarterly Results (4QFY19); Net Profit Up 7919.8% (Quarterly Result Update)

May 13, 2019 | Updated on May 13, 2019

For the quarter ended March 2019, STRIDES PHARMA SCIENCE has posted a net profit of Rs 650 m (up 7919.8% YoY). Sales on the other hand came in at Rs 8 bn (up 26.4% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

ABBOTT INDIA Announces Quarterly Results (3QFY19); Net Profit Up 1.4% (Quarterly Result Update)

Feb 12, 2019 | Updated on Feb 12, 2019

For the quarter ended December 2018, ABBOTT INDIA has posted a net profit of Rs 1 bn (up 1.4% YoY). Sales on the other hand came in at Rs 9 bn (up 7.5% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

More Views on News

Most Popular

Buying these Eight Stocks is Like Owning Your Own Business(Profit Hunter)

Sep 5, 2019

Everyone dreams of owning a business. Here is your chance.

7 Stocks to Buy in the Market Today(The 5 Minute Wrapup)

Sep 5, 2019

The stock market had a four-year bull run starting September 2013. Are we seeing a similar pattern now?

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

This Company Will Do Well Despite the Slowdown(The 5 Minute Wrapup)

Sep 11, 2019

How financial inclusion provides a big runway for this stock recommendation.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

ABBOTT INDIA SHARE PRICE


Sep 18, 2019 03:33 PM

TRACK ABBOTT INDIA

  • Track your investment in ABBOTT INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

ABBOTT INDIA 5-YR ANALYSIS

COMPARE ABBOTT INDIA WITH

MARKET STATS